福州大学郑寿添研究团队报道了具有fenton样反应活性的高生物相容性多氧化钨酸盐，用于肿瘤的有效化学动力学治疗。相关研究成果发表在2024年12月16日出版的国际学术期刊《德国应用化学》。

将芬顿化学和纳米药物整合到癌症治疗中，显著促进了化学动力学治疗（CDT）的发展。纳米多金属氧酸盐（POMs）具有可逆的氧化还原特性，通过探索其在肿瘤环境中的芬顿样催化反应，在开发优秀的CDT药物方面显示出巨大的潜力。然而，此类研究尚处于起步阶段。

该文中，研究人员报告了通过简单的“一锅”溶剂热反应以克级高产率合成新的晶体锑钨酸盐{Dy₂Sb₂W₇O₂₃(OH)(DMF)₂(SbW₉O₃₃)₂}（1，DMF=N，N-二甲基甲酰胺）。1不仅表现出可溶性和水稳定的POM纳米簇，而且对羟基自由基产生的芬顿样反应具有优异的催化活性。

进一步的生物医学研究表明，1可以触发细胞凋亡并促进脂质过氧化，对B16-F10小鼠黑色素瘤癌症细胞表现出高的细胞毒性和选择性，IC50值为4.75μM。特别是，1可以在体内抑制黑色素瘤的生长，具有良好的生物安全性，在70μg/kg的剂量下，肿瘤体积减少了5.2倍，体重减轻了76.0%。

该项研究不仅首次证明了抗肿瘤药物在CDT药物开发中的巨大潜力，还为新型抗癌药物的开发提供了新的见解和方向。

附：英文原文

Title: A Highly Biocompatible Polyoxotungstate with Fenton-like Reaction Activity for Potent Chemodynamic Therapy of Tumors

Author: Hui-Ping Xiao, Man-Yi Du, Xian-Bin Sun, Ruo-Fei Xu, Dong-Miao Li, Sheng-Nan Yue, Ping-Wei Cai, Rong-Zhi Sun, Zi-Zhong Zhang, Xing Huang, Xin-Xiong Li, Yu Gao, Shou-Tian Zheng

Issue&Volume: 2024-12-16

Abstract: Integrating Fenton chemistry and nanomedicine into cancer therapy has significantly promoted the development of chemodynamic therapy (CDT). Nanoscale polyoxometalates (POMs), with their reversible redox properties, exhibit promising potential in developing outstanding CDT drugs by exploring their Fenton-like catalytic reactivity in tumor environments. However, such research is still in its infancy. In this work, we report the synthesis of a new crystalline antimonotungstate {Dy2Sb2W7O23(OH)(DMF)2(SbW9O33)2} (1, DMF = N, N-dimethylformamide) with gram-scale high yield via a facile "one-pot" solvothermal reaction. 1 exhibits not only a soluble and water-stable POM nanocluster, but also excellent catalytic activity for hydroxyl radical-generating Fenton-like reactions. Further biomedical studies reveal that 1 can trigger cell apoptosis and promote lipid peroxidation, exhibiting high cytotoxicity and selectivity towards B16-F10 mouse melanoma cancer cells with an IC50 value of 4.75 μM. Especially, 1 can inhibit melanoma growth in vivo with favorable biosafety, achieving a 5.2-fold reduction in tumor volume and a weight loss of 76.0% at the dose of 70 μg/kg. This research not only demonstrates the immense potential of antimonotungstates in CDT drug development for the first time but also provides new insights and directions for the development of novel anticancer drugs.

DOI: 10.1002/anie.202422949

Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202422949